About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139-4133
Blueprint Medicines Corporation News and around…
Latest news about Blueprint Medicines Corporation (BPMC) common stock and company :
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.
Zai Lab Limited(NASDAQ: ZLAB) andBlueprint Medicines Corporation(NASDAQ: BPMC) have announced anexclusive ...
-- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands global development of Blueprint Medicines’ next-generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BLU-701 to Greater China -- -- Blueprint Medicines to receive $25 million upfront payment, up to $590 million in potential future milestone payments, and royalties -- CAMBRIDGE, Mass., SHANGHAI and SAN FRANCISCO, Nov. 09, 2021 (
Blueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan. Discovered by Blueprint Medicines, BLU-945 and BLU-701 are investigational next-gener
In this article, we discuss the 10 biggest stock picks in Eric Bannasch’s portfolio. If you want to skip our detailed analysis of Bannasch’s history, investment philosophy, and hedge fund performance, go directly to Eric Bannasch Portfolio: 5 Biggest Stock Picks. Serving as its portfolio manager, Eric Bannasch is the founder of the New York-based […]
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on November 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 24,373 shares of its common stock and an aggregate of 12,183 restricted stock units (RSUs) to eighteen new employees under Blueprint Medicines' 2020 Induceme
Blueprint Medicines (BPMC) misses earnings and revenue estimates for the third quarter of 2021. Yet, the stock price surges as the company provides encouraging pipeline updates.
BPMC earnings call for the period ending September 30, 2021.
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -18.34% and -39.72%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner ...
Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the third quarter ended September 30, 2021.
Blueprint Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma ...
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 28, 2021 to report its third quarter 2021 financial results and provide a corporate update.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree US.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Blueprint Medicines Corp (BPMC), where a total of 2,982 contracts have traded so far, representing approximately 298,200 underlying shares. That amounts to about 78.7% of BPMC's average daily trading volume over the past month of 378,930 shares..
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines' President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 12:30 p.m. ET.
Blueprint Medicines (NASDAQ:BPMC) has had a great run on the share market with its stock up by a significant 12% over...
I made 63 bullish calls involving 45 companies in 2019. Here are the winners, the stinkers, and everything in between.
Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.
Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.09% and -4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly ...
Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2021.